Both the name and mission at Flx Bio Inc. are clear throwbacks to predecessor Flexus Biosciences Inc., which was picked up in February by New York-based Bristol-Myers Squibb Co. (BMS) in a potential $1.25 billion takeover that included $800 million up front. (See BioWorld Today, Feb. 24, 2015.)
Top management at Flx is new, including CEO Brian Wong, recruited from Five Prime Therapeutics Inc., of South San Francisco, where he served as senior vice president of research and head of immuno-oncology (IO). Wong previously held leadership roles at Roche AG and Rigel Pharmaceuticals Inc.
Even though it's early days, "I think Flx Bio is positioned to become a leading IO company," Wong said. "And the way we're going to do that is to leverage our drug discovery expertise and immunology expertise. We have an incredible team here that